Clinical readout
TREMFYA improves axial PsA
In the 411-participant Phase 4 STAR study, TREMFYA improved axial disease activity versus placebo at week 24 in biologic-naïve adults with psoriatic arthritis and MRI-confirmed axial inflammation. Mean BASDAI scores fell by 3.3 and 2.9 points with four-weekly and eight-weekly TREMFYA, respectively, versus 2.1 with placebo.
MRI-assessed sacroiliac inflammation also declined more with TREMFYA. No new safety signals were identified.
The four-weekly regimen is not approved in the United States, and physical-function improvement with eight-weekly dosing did not reach statistical significance.
Written by Gosset from public sources. Source types: Press release · News article. Sources are available to Gosset users. Log in to see them.